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NC-ND license (http://creativecommoBackground: There have been several reports of congenital malformations in the offspring of
mothers who took valproic acid (VPA) during pregnancy as a treatment for epilepsy.
Methods: Herein, we describe four cases with typically similar facial features of fetal valpro-
ate syndrome accompanied to minor skeletal abnormalities.
Results: The first case was a 16-month-old girl, presenting with facial dysmorphism, and finger
abnormalities. Her mother took VPA (1500 mg/d) up to the 10th gestational week and at a
dosage of 1000 mg/d through the pregnancy. The second patient was 5-year-old boy with
speech disability, bilateral cryptorchidism, facial dysmorphism, and finger abnormalities
whose mother took VPA (1000 mg/d) through pregnancy. The third 19-month-old patient was
the brother of the second patient who had facial dysmorphism, bilateral cryptorchidism,
and finger abnormalities. His mother also took VPA (1000 mg/d) through pregnancy. The fourth
3-year and 6 month-old boy with minor facial dysmorphism and sternum deformity was
exposed to VPA (500 mg/d) in utero.
Conclusion: In conclusion, there is a recognizable spectrum of abnormalities in some infants
exposed to VPA without dose-depence and the common facial dysmorphic features and minor
skeletal abnormalities that may occur within the both low and high dose VPA use.
Copyright ª 2016, Taiwan Pediatric Association. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).1. Introduction
The use of valproic acid (VPA) monotherapy in the 1st
trimester of pregnancy was associated with significantly
increased risks of major and minor malformations,
including a 20-fold increase in neural tube defects (NTDs),of Pediatric Genetics, Meram Me
l.com (H. Mutlu-Albayrak).
Mutlu-Albayrak H, et al., Fetal V
1.009
016.01.009
ediatric Association. Published by
ns.org/licenses/by-nc-nd/4.0/).cleft lip and palate, cardiovascular abnormalities, genito-
urinary defects, developmental delay, endocrinological
disorders, limb defects, and autism, compared with the risk
without the use of antiepileptic drugs (AEDs).1
VPA causes dose-related teratogenic effects in all spe-
cies investigated (monkeys, rodents, rabbits); these includedical Faculty, Necmettin Erbakan University, Konya, Turkey.
alproate Syndrome, Pediatrics and Neonatology (2016), http://
Elsevier Taiwan LLC. This is an open access article under the CC BY-
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+ MODELskeletal malformations and craniofacial defects. The most
common malformations in humans are cardiac and NTDs.2
Many previous cases and studies focused on the associ-
ated major anomalies but overlooked the minor musculo-
skeletal abnormalities. However, substantial minor skeletal
abnormalities were often reported.3
The facial features in infants exposed to VPA in infancy
were first analyzed in detail by DiLiberti et al.4 The
commonly recognized features are epicanthal folds con-
necting with an infraorbital crease or groove, a flat nasal
bridge, a small nosewith anteverted nostrils, a long upper lip
with relatively shallow philtrum, a relatively small mouth
with downturned angles, and a thin upper vermilion border.5
We report four cases with typically similar facial fea-
tures to VPA exposure in utero, accompanied by minor
skeletal abnormalities.
2. Case Reports
2.1. Case 1
A 16-month-old girl was referred with limited extension in
the fingers of both hands. She was born full-term weighing
3000 g by cesarean section (breech presentation). Her par-
ents did not have consanguineous relations and she was the
first child of the family. Her mother was a 22-year-old with a
12-year history of epilepsy. Before becoming pregnant she
had been taking 1500 mg of VPA daily (in 3  500 mg doses).
She discovered her pregnancy at the 10th week of gestation.
VPA treatment was set at a dose of 1000 mg daily by an
obstetrician from this gestational week and the mother wasFigure 1 Clinical a
Please cite this article in press as: Mutlu-Albayrak H, et al., Fetal
dx.doi.org/10.1016/j.pedneo.2016.01.009recommended to use folic acid during pregnancy. She used
1000mgofVPA (500mg twice daily) and folic acid (5mg/d) up
to birth. Her seizure disorder was well-controlled.
The patient was able to hold her head steady while
sitting at the 4th month and able to sit unsupported at the
7th month. She spoke her first word at the 12th month. On
examination, her weight was 11 kg (50th percentile), height
was 75 cm (10th percentile) and fronto-occipital head
measurement was 45 cm (10the25th percentile). She had a
narrow bifrontal diameter, round face, short neck, full
cheeks, telecanthus, broad and low nasal bridge, small
nose, long and smooth philtrum, thin upper vermillion
border, downturned angles of the mouth, pointed chin,
posteriorly rotated ears with attached earlobes (Figures 1A
and 1B). Her thumbs were structured proximally. She had a
camptodactyly deformity on the right thumb, 3rd and 4th
fingers, left 4th and 5th fingers and also overriding on the
left 2nd and 4th toes (Figures 1C, 1D and 1E). Her echocar-
diography revealed no cardiac structural defect. No central
nervous system abnormality was identified on magnetic
resonance imagining (MRI). No urinary system abnormalities
were detected on abdominal ultrasonographic screening.
The patient was recommended physical therapy exercises
for finger anomalies.
2.2. Cases 2 and 3
Case 2, a 5-year-old boy, was admitted to the Pediatric
Neurology Department with a speech disability. He was
born by cesarean section (cephalopelvic disproportion) at
the 34th gestational week to a 21-year-old mother. Hisspects of Case 1.
Valproate Syndrome, Pediatrics and Neonatology (2016), http://
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+ MODELmother had epilepsy and had used VPA since her 1st decade.
She started to use folic acid (5 mg daily) supplementation
from the 4th week of preconception to the 3rd trimester and
continued taking VPA (1000 mg twice daily) throughout the
pregnancy. At the 2nd trimester, intra-abdominal acid was
visualized on the fetal ultrasonography. After delivery the
patient was hospitalized with respiratory insufficiency and
nonimmune hydrops fetalis. No evidence was found in
terms of congenital cytomegalovirus, herpes virus and
toxoplasma virus infections. Cardiac examination and
echocardiography screening were normal. At Postnatal Day
21 he was discharged in healthy condition. He was able to
hold his head steady at the 8the9th month and walked at
the 18th month. At 2 years old he started to speak one or
two words but never gained the ability to make sentences.
He was operated on due to bilateral cryptorchidism at the
age of 12 months. On examination, his weight was 21 kg
(50the75th percentile), height was 120 cm (90the97th
percentile), and fronto-occipital head measurement was
48.5 cm (<3rd percentile). He had telecanthus, flaring
eyebrows, a broad nasal ridge, short nose, midface hypo-
plasia, full cheeks, long and smooth philtrum, downturned
corners of the mouth, low-set ears, pointed chin, pectus
excavatum, broad fingers, hypoplastic finger nails, left 5th
finger clinodactyly and medial angulation of the left 3the4th
toes (Figure 2). No additional abnormalities were revealed
by cranial MRI scan and abdominal ultrasonography. He was
advised to take speech therapy.
Case 3 (brother of Case 2) was a 19-month-old boy, who
was called for examination on learning that his motherFigure 2 Clinical a
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dx.doi.org/10.1016/j.pedneo.2016.01.009had taken VPA (1000 mg daily) throughout the second
pregnancy. She did not use folic acid supplementation
regularly. He was born at full-term by cesarean section.
There was no history of pre- or postnatal complications
except for the identification of a ventricular septal defect
by echocardiography when he was 1 month old. He could
walk by the 17th month and speak by the age of 12
months. On examination his weight was 11 kg (10the25th
percentile), height was 83 cm (25the50th percentile), and
fronto-occipital head measurement was 45 cm (<3rd
percentile). He had a high forehead, telecanthus, a broad
nasal ridge, short nose, midface hypoplasia, long and
smooth philtrum, thin upper vermillion border, down-
turned angles of the mouth, and low-set ears (Figure 3A).
Testes were not palpable bilaterally. He had pes planus,
bilateral mega-halluces, and hypoplasia of the 5th toes
with cutaneous syndactyly on the left 4the5th toes. His
left 2nd, 3rd and 4th toes were laterally angulated and the
right 4th toe was medially angulated (Figures 3B and 3C).
Small joint contractures were not observed on the hands.
No additional abnormalities were demonstrated on cranial
MRI and abdominal ultrasonography.2.3. Case 4
A 3.5-year-old boy was referred to the Pediatric Genetics
Clinic because of dysmorphic face and sternum deformity.
He was born by cesarean section (polyhydroamnios) at the
38th gestational week to a 25-year-old mother as her secondspects of Case 2.
alproate Syndrome, Pediatrics and Neonatology (2016), http://
Figure 3 Clinical aspects of Case 3.
Figure 4 Clinical aspects of Case 4.
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+ MODELchild. The mother was epileptic and had used VPA for 15
years. She was taking VPA (500 mg daily, controlled release
formulation) when she became pregnant. She continued to
take VPA at the same dosage throughout the pregnancy. She
started to use folic acid (5 mg daily) supplementation until
the 8th week but did not use it regularly. The mother took
VPA (500 mg daily) during her first pregnancy and had a
healthy baby. The patient could walk and speak by 2e3
years. On examination his weight was 12 kg (10th percentile),
height was 106 cm (50th percentile), and fronto-occipital
head measurement was 45 cm (< 3rd percentile). He had
upswept frontal hair, a high forehead, narrow bifrontal
diameter, broad nasal bridge, short nose, anteverted nares,
a long and smooth philtrum, thin upper vermillion border,
downturned angles of the mouth, clefting on the lower right
central incisor and pectus excavatum (Figure 4). An ostium
secundum atrial septal defect was detected by echocardi-
ography screening. No additional anomalies were depicted
on cranial MRI and renal ultrasonography.
3. Discussion
VPA has been associated with a variety of major and minor
malformations, including a 20-fold increase in NTD, cleft lip
and palate, cardiovascular abnormalities, genitourinary de-
fects, developmental delay, endocrinological disorders, limb
defects, and autism.1 On account of the observed terato-
genic effects of high-dosage (>1000 mg) VPA exposure in
utero, VPA was offered at a dose not exceeding 1000 mg and
with folate supplementation for the prevention of NTD in
most cases. Although a number of cohort studies of women
exposed to VPA in pregnancy showed an association with a
range of malformations, individually these studies had
limited power to detect excess risks of specific congenital
malformations and overlooked the minor abnormalities.6
Many studies have indicated that women taking VPA
during pregnancy had a twofold to 16-fold greater chance
of having a child with a major congenital malformation,
with dose-dependent characteristics.7e9 The rate of major
congenital malformations up to 1 year with VPA < 700 mg
daily was 24%, for 700e1500 mg it was 50%, and for
1500 mg it was 24%.2 The most common were cardiac
malformations and NTDs. Almost all reported dose-related
series were of major congenital malformations. In Case 1
the child had no major congenital malformation, having
been exposed to maximum dose VPA (1500 mg/d) up to the
10th gestational week. Case 2 had bilateral cryptorchidism.Please cite this article in press as: Mutlu-Albayrak H, et al., Fetal
dx.doi.org/10.1016/j.pedneo.2016.01.009Case 3 (1000 mg/d VPA throughout the pregnancy) had a
ventricular septal defect in addition to bilateral cryptor-
chidism. Case 4 (500 mg/d VPA) had a small secundum atrial
septal defect, detected in utero (Table 1).
Most available studies identified that abnormalities of
the musculoskeletal system were the most common sys-
temic abnormalities associated with the use of VPA in
pregnancy.10e12 These abnormalities are variable, including
the following: contractions of the small joints and the
presence of long overlapping fingers (36%), followed by foot
deformity (30%), thoracic cage abnormalities (7%), and nail
abnormalities (10%).3 Skeletal deformities have also been
observed in animal models.11,13 The most frequent mal-
formations were fusion, agenesis and duplication of verte-
brae, fusion or agenesis of ribs, fusion and asymmetry of
sternebrae, and extra sternebrae.14 There were flexion
contractures of fingers and toe overlapping in Case 1;
pectus excavatum, left 5th finger clinodactyly, bilateral toe
angulation deformities in Case 2; bilateral 5th toe hypo-
plasia and toe angulation deformities in Case 3; and pectus
excavatum in Case 4. Kozma3 reported two siblings exposedValproate Syndrome, Pediatrics and Neonatology (2016), http://
Table 1 Comparative clinical features of the cases.
Age (sex) Valproate dose
(exposure time)
Brain abnormalities Cardiac
abnormalities
Urogenital
abnormalities
Musculoskeletal system
abnormalities
Developmental
delay
Our cases
Case 1 16 mo (female) 1500 mg (preconception
to 10th wk gestation)
1000 mg (10th wk
gestation to delivery)
d d d Small hand joint
contractures
and toe overlapping
d
Case 2 5 y (male) 1000 mg (throughout
pregnancy)
d d Bilateral
cryptorchidism
Pectus excavatum,
left 5th finger clinodactyly,
bilateral toe angulation
deformities
Speech delay
Case 3 19 mo (male) 1000 mg (throughout
pregnancy)
d Ventricular
septal defect
Bilateral
cryptorchidism
Bilateral 5th toe hypoplasia
and toe angulation
deformities
-
Case 4 3.5 y (male) 500 mg (throughout
pregnancy)
d Secundum atrial
septal defect
d Pectus excavatum Gross motor
delay
Winter et al16 1987
Case 5 2 mo (male) 1600 mg (throughout
pregnancy)
N/A N/A Hypospadias Pectus excavatum,
polydactyly of the right 5th
finger and clinodactyly of
the left 5th finger with
mild talipes
N/A
Case 6 1d (male) 2400 mg (throughout
pregnancy)
N/A Ventricular
septal defect
N/A 2nd and 4th toes of both
feet overrode the 3rd toes
N/A
Case 7 3 mo (male) 2400 mg (throughout
pregnancy)
N/A Pulmonary
stenosis
Hypospadias The 5th toes of both feet
were proximally placed and
overlapped the 4th
toes
Gross motor
delay
Kozma3 2001
Case 8 3 y (male) 1500 mg (throughout
pregnancy)
d d d Ulnar deviations of the fingers
of both hands, mild contractures
of the terminal phalanges of 2nd
to 4th digits, pes planus,
a lordotic curvature of the spine
Gross motor
delay
Case 9 8 mo (male) 1500 mg (throughout
pregnancy)
Prominence of the
ventricles and of
the cortical sulci in
the frontal region,
with cranial
asymmetry.
- The left testicle
was undescended,
two small cysts
around the
collecting
system of the
right kidney
Curved middle toes bilaterally,
contractures of the right index
finger and the left middle finger,
talipes equinovarus of the
right foot, and metatarsus
adductus of the left foot
Gross motor
delay
(continued on next page)
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dx.doi.org/10.1016/j.pedneo.2016.01.009to VPA 1500 mg/d, with contractures of the small joints and
spinal and foot deformity without significant major mal-
formation (Table 1). Schorry et al15 reported five siblings
with finger and nail abnormalities, where each one was
exposed to VPA of minimum 500 mg/d and maximum
2000 mg/d. Winter et al16 reported three cases with ster-
num and finger abnormalities accompanied by cardiac
malformation, who were exposed to VPA doses between
1600 mg and 2400 mg/d in utero.
VPA was also identified as a potential risk for develop-
mental delay, cognitive impairment, attention deficit hy-
peractivity disorder, and autism, exceeding the risks for
other AEDs.17,18 Although variation in study designs, out-
comes, and cognitive tests precluded synthesis of these
data into meta-analyses, all researchers reported devel-
opmental delays and cognitive deficits that were associated
with VPA use in pregnancy. The most prominent effect was
on verbal intelligence quotient. The Ankara Developmental
Screening Inventory was applied to all cases. Case 2 suf-
fered from delay of speech development and Case 4 had
significant motor delay; however, there was no gross motor
delay in Case 1 or 3. A common feature of all our cases was
the presence of minor facial dysmorphism. All cases were
microcephalic except for Case 1. Telecantus (3/4), low
nasal bridge with short nose (4/4), long smooth philtrum
with a thin vermillion border (4/4), and downturned angles
of the mouth (4/4) were the most common facial dysmor-
phic features (Table 2). It should be noted that the feature
of downturned angles of the mouth was infrequently
specified in the literature on similar cases. As all our cases
had the typical facial appearance of fetal valproate syn-
drome (FVS), it was clear that this developed when the
fetus was exposed to between 500 mg/d and 1000 mg/d.
The teratogenicity of an exposure is also influenced by
both the maternal and fetal genotypes.1 However, most
women with epilepsy have healthy children. While some in-
fants exposed to an anticonvulsant drug in utero had abnor-
malities, others did not. Genetic differences in the fetal
response to medications probably play a role. The risk of
recurrence of FVS in a subsequent pregnancy exposed to VPA
would therefore appear to be high, possibly due to inherent
problems with the metabolism of VPA in the mothers con-
cerned. A hypothesis that links a reduced level of expression
of placental drug transporters and AEDs prescribed during
pregnancy with birth defects and neurodevelopment impair-
ments in later childhood opens potential avenues for further
research.19 Naturally-occurring genetic variations causing
differences in the expression of transport proteins are likely
to be an important cause of interindividual variability in
pharmacokinetics and pharmacodynamics ofmanydrugs. The
effects that polymorphisms have on placental expression of
these transporters undoubtedly contribute to fetal suscepti-
bility. The “common ground” of the four mothers in the study
was their long-term use of VPA (10 years). As well as a ge-
netic fetal susceptibility, previously introduced somatic
epigenetic mutations have also been suggested for long-term
drug usage. Previous studies demonstrated that VPA, a direct
inhibitor of histone deacetylase, could induce histone
hyperacetylation and other epigenetic changes such as his-
tone methylation and DNA demethylation.20 Malm et al21
described three families in whom the occurrence of FVS in
all the siblings strongly suggested hereditary susceptibility toValproate Syndrome, Pediatrics and Neonatology (2016), http://
Table 2 Craniofacial dismorphological features of the cases.
Case no.
1 2 3 4 5 6 7 8 9 10 11 12 13 14
Microcephaly  þ þ þ þ þ N/A       þ
Narrow bifrontal diameter þ   þ þ N/A þ  þ     
High-forehead   þ þ þ N/A  þ þ     
Epicanthal folds     þ N/A        
Telecanthus/Hypertelorismus þ þ þ  þ N/A þ þ þ þ þ þ þ þ
Low nasal bridge with short nose þ þ þ þ þ N/A þ þ þ þ þ þ þ þ
Anteverted nares    þ  N/A  þ þ   þ  
Midface hypoplasia  þ þ   N/A  þ þ þ  þ þ 
Long smooth filtrum with a thin
vermillion border
þ þ þ þ þ  þ þ þ þ þ þ þ þ
Micrognathia    þ  N/A  þ þ     
Downturned angles of the mouth þ þ þ þ  N/A þ       
Low-set posteriorly rotated ears þ    þ N/A þ þ þ   þ þ 
N/AZ not available.
Fetal Valproate Syndrome 7
+ MODELa VPA-induced adverse outcome. The mother of Case 4 took
VPA (500mg/d) through her previous pregnancy and the baby
had neither major nor minor malformations. However, there
were minor malformations in Cases 2 and 3.
In conclusion, there is a recognizable nondose-
dependent spectrum of abnormalities in some infants
exposed to VPA. Though minor anomalies were not widely
reported in a large number of antiepileptic drug teratology
investigations, common facial dysmorphic features and
minor skeletal abnormalities could occur with both low-
and high-dose VPA use.
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